Judit Cubedo, CEO of GlyCardial, finalist for the EU Prize for Women Innovators 2020 Blog Post

Judit Cubedo, co-founder and CEO of GlyCardial Diagnostics, is one of the twenty-one women selected as finalists for the EU Prize for Women Innovators 2020, an award given annually to the most talented and inspiring entrepreneurs in Europe. The company led by Judit, which is based in the Barcelona Science Park, is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia. The award winners will be announced at the European Research and Innovation Days taking place on 22-24 September 2020.

 

Promoting scientific careers in times of COVID-19 Blog Post

Against the backdrop of the major challenges posed by the COVID-19 pandemic, which has underscored the crucial role science and technology play in our society, the Barcelona Science Park is stepping up its commitment to persuading young people to choose scientific careers by holding a new edition of Batx2Lab, a pioneering programme which has inspired the STEM talent of more than 700 young people.

 

Gorka Etxebarria, new Chief Scientific Officer of Nostrum Biodiscovery Blog Post

Nostrum Biodiscovery (NBD) has appointed Dr. Gorka Etxebarria as new Chief Scientific Officer. Dr Etxebarria has a solid career linked to drug discovery projects in the pharmaceutical industry. His incorporation comes after the signing of Ezequiel Mas as new company CEO, to pilot a new stage of growth as a global provider of leading molecular simulation technologies applied to drug discovery and design.

 

Juan Carlos Kaski, new Chief Medical Officer of GlyCardial Diagnostics Blog Post

GlyCardial Diagnostics, based in the Barcelona Science Park, announces the appointment of Prof. Juan Carlos Kaski as Chief Medical Officer. The company –a spinoff of the Research Institute of the Hospital de la Santa Creu i Sant Pau (IR-HSCSP) and the Spanish National Research Council (CSIC), is conducting a clinical trial to validate the performance of Apo J-Glyc as a novel biomarker for the early detection of Myocardial Ischaemia.